Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients

ConclusionsIn this large cohort, the rate of discontinuation of dolutegravir because of neuropsychiatric adverse events was significantly higher than for other INSTIs, at almost 6% within 12 months. Despite the limitations of this retrospective study, the almost three‐fold higher discontinuation rates observed amongst women and older patients underscore the need for further investigation, especially in patient populations usually underrepresented in clinical trials.

Source: HIV Medicine - October 31, 2016 Category: Infectious Diseases Authors: C Hoffmann, T Welz, M Sabranski, M Kolb, E Wolf, H ‐J Stellbrink, C Wyen Tags: Original Research Source Type: research